A Phase 1 interventional study of Comparator: Placebo 5mg (run in) and Donepezil 5 - 10 mg in Alzheimer's Disease, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2015-08-25.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Alzheimer Disease by Merck & Co., Inc — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Merck & Co., Inc.
Among the 31 studies in Alzheimer Disease by Merck & Co., Inc, this one is the 9th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2008, is one of 18 in phase 1, and was the 7th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →1 of the 31 studies in Alzheimer Disease by Merck & Co., Inc is open now, in 11 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 8 more countries
Ages 50–85
By country, each count listing its studies:
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 9 · Phase 3 4
First in 2003; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 34 across the 29 interventional studies, 11 across the 1 observational. Of the 29 that completed or were terminated, 20 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 31 studies in Alzheimer Disease by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the performance of the CogState computerized neuropsychological battery, Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) and Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) in participants with mild-to-moderate Alzheimer's disease (AD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
There will be a 14 day period when all participants will receive placebo, followed by 5 mg donepezil, once daily for 14 days then titrated to 10 mg donepezil once daily for 70 days. Participants may then receive open-label donepezil for an additional 24 weeks.
Drug: Comparator: Placebo 5mg (run in) · Drug: Donepezil 5 - 10 mg · Drug: Donepezil 10 mg
There will be a 14 day period when all participants will receive placebo. Participants will take placebo capsules orally, once daily for 84 days. Participants may then receive open-label donepezil for an additional 24 weeks.
Drug: Comparator: Placebo 5mg (run in) · Drug: Comparator: Placebo 5-10 mg · Drug: Donepezil 10 mg
Matching placebo to donepezil - 5 mg capsules orally for 14 day run in prior to randomization.
Donepezil 1 capsule (5 mg) orally, once daily for 14 days. Donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84).
Matching placebo to donepezil, 1 capsule (5 mg) orally, once daily for 14 days. Matching placebo to donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84).
Donepezil 2 capsules (total 10 mg) orally, once daily for 24 weeks, from day 85 (optional).
Change in Mean Computer-based Cognitive Assessment (CogState) Composite Score at Week 4
CogState is a simple, brief computerized neuropsychological battery to evaluate cognitive impairments characterizing mild-to-moderate Alzheimer's Disease (AD). The composite CogState assesses attention and memory functions - including Verbal episodic memory, Visual Episodic Memory, Psychomotor function, Visual attention and working memory. CogState scores are measured on a linear scale (with no maximum score) and a reduction in scores compared to baseline indicates an improvement in cognitive functions. Reported here is the change in the CogState Composite Score at Week 4 compared to baseline.
Time frame: Baseline and 4 weeks
Evaluate the Efficacy of Donepezil by Determining the Change in Mean CogState Composite Score at Week 2, Week 8 and Week 12
CogState is a simple, brief computerized neuropsychological battery to evaluate cognitive impairments characterizing mild-to-moderate Alzheimer's Disease (AD). The composite CogState assesses attention and memory functions - including Verbal episodic memory, Visual Episodic Memory, Psychomotor function, Visual attention and working memory. CogState scores are measured on a linear scale (no maximum score) and a reduction in scores compared to baseline indicates an improvement in cognitive functions. Reported here is the change from baseline in the CogState Composite Score at Weeks 4, 8 and 12.
Time frame: Baseline and 2 weeks, 8 weeks and 12 weeks
Evaluate the Efficacy of Donepezil by Determining the Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score at Week 4, Week 8 and Week 12
The ADAS-Cog is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation and praxis using an 11-point AD Assessment Scale. It has a minimum score of 0 and a maximum severity score of 70, and a higher score indicates more impairment. A reduction in scores compared to baseline indicates an improvement in cognitive functions. Reported here is the change in the ADAS-Cog score at Weeks 4, 8 and 12 compared to baseline.
Time frame: Baseline and 4 weeks, 8 weeks and 12 weeks.
| Milestone | Donepezil 5-10 mg | Placebo |
|---|---|---|
| Started | 53 | 53 |
| Completed | 49 | 47 |
| Not completed | 4 | 6 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Investigator decision | 1 | 2 |
CogState is a simple, brief computerized neuropsychological battery to evaluate cognitive impairments characterizing mild-to-moderate Alzheimer's Disease (AD). The composite CogState assesses attention and memory functions - including Verbal episodic memory, Visual Episodic Memory, Psychomotor function, Visual attention and working memory. CogState scores are measured on a linear scale (with no maximum score) and a reduction in scores compared to baseline indicates an improvement in cognitive functions. Reported here is the change in the CogState Composite Score at Week 4 compared to baseline.
| Score on a scale | Donepezil 5-10 mg | Placebo |
|---|---|---|
| Change in Mean Computer-based Cognitive Assessment (CogState) Composite Score at Week 4 | -0.10 ± 0.07 | -0.07 ± 0.06 |
CogState is a simple, brief computerized neuropsychological battery to evaluate cognitive impairments characterizing mild-to-moderate Alzheimer's Disease (AD). The composite CogState assesses attention and memory functions - including Verbal episodic memory, Visual Episodic Memory, Psychomotor function, Visual attention and working memory. CogState scores are measured on a linear scale (no maximum score) and a reduction in scores compared to baseline indicates an improvement in cognitive functions. Reported here is the change from baseline in the CogState Composite Score at Weeks 4, 8 and 12.
| Score on a scale | Donepezil 5-10 mg | Placebo |
|---|---|---|
| Week 2 (N=38, N=43) | -0.2 ± 0.07 | -0.006 ± 0.06 |
| Week 8 (N=38, N=40) | -0.1 ± 0.07 | -0.02 ± 0.07 |
| Week 12 (N=38, N=41) | -0.2 ± 0.07 | -0.09 ± 0.07 |
The ADAS-Cog is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation and praxis using an 11-point AD Assessment Scale. It has a minimum score of 0 and a maximum severity score of 70, and a higher score indicates more impairment. A reduction in scores compared to baseline indicates an improvement in cognitive functions. Reported here is the change in the ADAS-Cog score at Weeks 4, 8 and 12 compared to baseline.
| Score on a scale | Donepezil 5-10 mg | Placebo |
|---|---|---|
| Week 4 (N=38, N=43) | 0.2 ± 0.8 | -0.3 ± 0.7 |
| Week 8 (N=37, N=40) | 0.07 ± 1.0 | -0.7 ± 1.0 |
| Week 12 (N=38, N=40) | -1.4 ± 1.0 | -1.0 ± 1.0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Donezepil 5-10 mg | — | 3/53 (5.7%) | 10/53 (18.9%) |
| Placebo | — | 0/53 (0%) | 9/53 (17%) |
| Event | Donezepil 5-10 mg | Placebo |
|---|---|---|
| Inguinal herniaGastrointestinal disorders | 1/53 | 0/53 |
| Head InjuryInjury, poisoning and procedural complications | 1/53 | 0/53 |
| Subdural haematomaInjury, poisoning and procedural complications | 1/53 | 0/53 |
| ConvulsionNervous system disorders | 1/53 | 0/53 |
| Urinary incontinenceRenal and urinary disorders | 1/53 | 0/53 |
| Event | Donezepil 5-10 mg | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 7/53 | 5/53 |
| DizzinessNervous system disorders | 3/53 | 4/53 |
| Age, Customized(Participants) | Donepezil 5-10 mg | Placebo | Total |
|---|---|---|---|
| Number | 53 | 53 | 106 |
| Sex: Female, Male(Participants) | Donepezil 5-10 mg | Placebo | Total |
|---|---|---|---|
| Female | 23 | 22 | 45 |
| Male | 30 | 31 | 61 |
No study locations are listed for this record.
The record gives a start of Dec 2008, a primary completion of Oct 2009 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.